With the advent of novel therapies for Alzheimer's disease, there is a pressing need for biomarkers that are easy to monitor, such as the amyloid-beta (Aβ) levels in the cerebrospinal fluid (CSF) and plasma. To gain a better understanding of the explanatory power of these biomarkers, we formulate and analyze a compartmental mathematical model for the Aβ accumulation in the brain, CSF and plasma, throughout the course of Alzheimer's treatment. Our analysis reveals that the total Aβ burden in the brain is dictated by a unitless quantity called the polymerization ratio, which is the product of the production and elongation rates divided by the product of the fragmentation and loss rates. In this ratio, the production rate and loss rate include a source and sink term, respectively, related to the intercompartmental transport. Our results suggest that production inhibitors are likely to reduce the Aβ levels in all three compartments. In contrast, agents that ingest monomers off of polymers, or that increase fragmentation or block elongation, may also reduce Aβ burden in the brain, but may produce little change in-or even transiently increase-CSF and plasma Aβ levels. Hence, great care must be taken when interpreting these biomarkers.
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INTRODUCTION
Alzheimer's disease (AD) is the third leading cause of death-behind cancer and cardiovascular disease-among the elderly in the U.S. Central to the pathogenesis of this progressive neurodegenerative disease is the polymerization (or fibrillization, as it is called in the AD context) of amyloid-beta (Aβ) protein, and its subsequent deposition in senile plaques (Selkoe, 1999) . Aβ is produced when two enzymes, β-secretase and γ -secretase, sequentially cleave Aβ from its larger protein, amyloid precursor protein (APP), which is expressed in the brain. Several novel treatment approaches have shown promise in pre-clinical studies, including the enhancement of Aβ clearance by an Aβ vaccine (Schenk et al., 1999; Bard et al., 2000; Weiner et al., 2000) , the reduction of Aβ production by a γ -secretase inhibitor (Wolfe et al., 1999; Felsenstein, 2000) , and the efflux of Aβ from the brain to the plasma by a monoclonal antibody (DeMattos et al., 2001 (DeMattos et al., , 2002 . While cognitive tests will provide the ultimate assessment of the efficacy of these and other agents (Janus et al., 2000) , it will still be important to estimate the Aβ burden in the brain. Unfortunately, it is currently not feasible to measure the Aβ level in the human brain in an unobtrusive manner. Hence, as these therapies enter clinical trials, a key challenge will be to infer treatment-induced changes in the Aβ burden in the brain from the Aβ levels in more easily monitored compartments, such as the cerebrospinal fluid (CSF) and the plasma. These inferences, which could conceivably be required for FDA approval of novel AD agents, need to be based on a solid understanding of the Aβ kinetics throughout the three interrelated compartments.
There exist several mathematical models that focus on either fibrillogenesis (Naiki et al., 1991; Lomakin et al., 1996; Naiki and Nakakuki, 1996; Harper and Lansbury, 1997; Lomakin et al., 1997; Walsh et al., 1997; Naiki et al., 1998; Inouye and Kirschner, 2000) or plaque formation (Hyman et al., 1995; Cruz et al., 1997; Urbanc et al., 1999) in the Alzheimer's brain, these studies neither consider the impact of treatment now allow for a continuously renewable source of Aβ from APP molecules. Recently, a mathematical analysis was undertaken of an agent that blocks amyloid formation by capping polymer ends (Masel and Jansen, 2000) . Also, in previous work (Craft et al., 2001) , we formulated and analyzed a mathematical model that tracks the dynamics of Aβ production and loss, and polymer elongation and fragmentation in the brain during the course of treatment. However, none of the above models consider the flow of Aβ between the brain, CSF and plasma. Although the transport of Aβ between the various compartments has been studied in recent years (Zlokovic et al., 1993; Ghersi-Egea et al., 1996; Martel et al., 1996; Poduslo et al., 1997; Mackic et al., 1998) , the impact of treatment on the Aβ kinetics in these three compartments has not been elucidated. Here we generalize our previous results by considering a three-compartment model, where Aβ is transported between the brain, CSF and plasma. Simple formulae and numerical results are presented that provide some insights into system behavior, and that
